JPMorgan analyst Anupam Rama raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $20 from $17 and keeps an Overweight rating on the shares. The firm adjusted models in the smid-cap biotech space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals initiated with a Peer Perform at Wolfe Research
- Oric Pharmaceuticals price target raised to $16 from $12 at Citi
- Oric Pharmaceuticals’ 2025 Restructuring: Potential Risks and Financial Implications
- Promising Potential of ORIC-944 in mCRPC Treatment Boosts Buy Rating and Price Target
- Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright